Pharmacological properties

Pharmacodynamics. bronkholitin — the combined medicine with the expressed antibechic, bronkhodilatiruyushchy action. complex effect of medicine is caused by properties of its main components: glautsina of hydrobromide and ephedrine of a hydrochloride. alkaloid glautsin oppresses the tussive center, without affecting at the same time a respiratory center. has slight bronkhospazmolitichesky and adrenolytic effect and does not cause accustoming and dependence on condition of observance of a route of administration and a dose.

Ephedrine is adrenomimetiky direct (stimulates alpha and beta receptors) and indirect (suppresses activity of an aminooxidase) actions. Causes release of noradrenaline and adrenaline from their depot. Ephedrine has spasmolytic effect on unstriated muscles of bronchial tubes. For a long time relaxes bronchial muscles that is caused by the expressed promoting effect on β ₂ - adrenergic receptors. Under the influence of ephedrine the hypostasis of a mucous membrane of bronchial tubes decreases and their gleam extends. Pharmacological researches of Bronkholitin syrup show that it reduces spastic action of a histamine on bronchial tubes.

Simplification of department of a phlegm and decrease in obstruction of bronchial tubes are caused by bronkhodilatiruyushchy effect of ephedrine.

Pharmacokinetics. Absorption. After oral administration glautsin and ephedrine are quickly and completely absorbed in a GIT.

Distribution. The C _max a glautsin in blood plasma is reached in 1.5 h after its reception.

Ephedrine is distributed by

in an organism with accumulation mainly in a liver, lungs, kidneys, a spleen and a brain.

Metabolism. Glautsin and ephedrine (small part) are metabolized in a liver.

Removal. Glautsin is excreted with urine in the form of metabolites and in not changed look.

T _½ ephedrine about 3-6 h make Eliminiruyetsya with urine mainly in not changed look.

Bronkholitin is recommended to apply

Indication

as a part of complex therapy of the diseases of a respiratory system which are followed by dry unproductive cough: acute and chronic bronchitis, tracheobronchitis, oh, pneumonia, bronchiectasias.

Use

is Applied orally after a meal.

Adults and children are aged more senior than 10 years: on 10 ml 3–4 times a day.

Children aged from 3 up to 5 years: on 5 ml of medicine divorced just before application in 10 ml of the cooled boiled water, 3 times a day; from 5 to 10 years — on 5 ml 3 times a day.

Duration of a course of treatment is 5–7 days.

Contraindication

Hypersensitivity to active ingredient or any auxiliary component of medicine.

an ischemic heart disease; heavy and/or uncontrollable AG; sharp myocardial infarction; heavy organic heart diseases with manifestations of a decompensation; thyrotoxicosis; pheochromocytoma; closed-angle glaucoma; a prostatauxe with an ischuria; insomnia.

Side effects

At use of medicine bronkholitin emergence of the following side reactions is possible

:

from the immune system: reactions of hypersensitivity (enanthesis, urticaria, feeling of an itch, Quincke's disease, bronchospasm);

from the respiratory system, bodies of a thorax: dispnoe;

from a cardiovascular system: violation of a warm rhythm and conductivity, tachycardia, premature ventricular contraction, arrhythmia, palpitation, increase in the ABP, myocardium ischemia, a stethalgia, violation of circulation in extremities;

from nervous system: headache, tremor, excitement, uneasiness, concern, insomnia, sedation, dizziness;

from digestive system: dryness in a mouth, anorexia, nausea, vomiting, a lock;

from an urinary system: urination difficulty, at patients with a prostatauxe the ischuria is possible;

from skin and mucous membranes: the strengthened sweating;

from sense bodys: disorder of vision;

others: short wind, weakness, increase a libido, a dysmenorrhea, a tachyphylaxis, tolerance with development of dependence (at prolonged use).

At the patients accepting ephedrine or pseudoephedrine, the myocardial infarction is noted very seldom.

Efedrin can act with

as a stimulator at children with night enuresis and to cause insomnia, also to have sedative effect at some children.

by

Special instructions

Owing to promoting effect on central nervous system and a possible sleep disorder does not recommend administration of medicament bronkholitin syrup after 16 h

to

to Appoint with care to patients with diabetes and a renal failure.

to Apply

with care at the patients inclined to development of medicinal dependence.

If in 5–7 days from the beginning of therapy the symptoms of a disease remain or the state worsens, it is necessary to see a doctor for assessment of expediency of further treatment.

At treatment by sympathomimetics including effects from a cardiovascular system can arise the medicine Bronkholitin. Data of post-market researches and also these literatures contain the known proofs about the exceptional cases of ischemia of a myocardium connected with application of beta-agonists (hydrochloride ephedrine). Patients with heart diseases (ischemic heart diseases, arrhythmia or heart failure) which use this medicament should be warned about need to ask for the help the doctor at a stethalgia or emergence of other symptoms of deterioration in a heart disease. It is necessary to pay special attention to assessment of such symptoms as dispnoe and a stethalgia as they can be both respiratory, and warm origin.

Glautsin's

hydrobromide should not be applied at productive cough which is followed by expectoration as there is a risk of an obturation of bronchial tubes as a result of a delay of a bronchial secret. In case of the labile ABP the consultation of the doctor is necessary. Drug should be used with extra care to patients with AG and a hyperplasia of a prostate. To apply with care because of risk of collapse as a result of sympatholytic action of a glautsin of hydrobromide.

Children and elderly people are more sensitive

to effect of ephedrine.

by

After prolonged use of ephedrine observes tolerance with development of dependence.

Bronkholitin contains 43.75 g of sucrose. At application each dose (5 ml) contains up to 2 g of sucrose in the recommended doses. Persons with the established intolerance of some sugars should consult with the doctor before accepting this medicine. Drug can be harmful to teeth.

Bronkholitin contains

up to 1.7 about. ethanol %. Each dose (5 ml) contains up to 0.069 g of alcohol. It is dangerous to patients with diseases of a liver, alcoholics, epilepsy, brain diseases. Content of alcohol should be considered at application by pregnant women.

Syrup contains in quality of excipients methylparahydroxybenzoate (E 218) and propilparagidroksibenzoat (E 216) which can cause allergic reactions (perhaps, slowed down).

ephedrine Content as a part of medicine can yield positive take at doping test at athletes.

Period of pregnancy and feeding by a breast. Not to apply in the I trimester of pregnancy and during feeding by a breast. There are no data on safety of application in ІІ a trimester therefore it is recommended to apply only in cases when the advantage for mother exceeds potential risk for a fruit.

Use of ephedrine in ІІІ the trimester can lead

to acceleration of ChSS at a fruit.

Children. It is recommended to children 3 years are more senior.

Ability to influence speed of response at control of vehicles or work with other mechanisms. Drug should be used with care at control of vehicles and work with the automated mechanisms because of effect of ephedrine. Ephedrine can cause a mydriasis and influence speed of response at control of vehicles and work with mechanisms.

Interaction

Bronkholitin can be applied along with antibiotics, febrifuges and vitamins. because of existence in composition of medicine of ephedrine effects of narcotic and sleeping medicines are weakened. at simultaneous application with cardiac glycosides, some sympathomimetics, quinidine, tricyclic antidepressants the risk of developing arrhythmias increases. similar effects can be observed also at simultaneous application with ergoalkaloida or oxytocin. at simultaneous application with reserpine perhaps sharp increase hell.

As ephedrine has properties both alpha, and beta-agonists, it is necessary to apply it with care at the patients who transferred an anesthesia with cyclopropane, a halothane or other flying anesthetics.

Ergoalkaloida's

, MAO inhibitors and oxytocin exponentiate pressor effect of ephedrine (risk of hypertensive crisis at simultaneous application). If the Bronkholitin medicament treatment is necessary, it is necessary to adhere to a two-week interval after phase-out of MAO inhibitors.

At the combined application with non-selective blockers of β-adrenoceptors the broncholitic effect of medicine decreases.

Sympathomimetics possess antagonistic action on antihypertensive effect of blockers of β-adrenoceptors.

Ephedrine can counteract neuronblokiruyushchy effect of a guanetidin that leads to loss of its hypotensive efficiency.

Ephedrine accelerates dexamethasone metabolism.

At the simultaneous Bronkholitin medicament treatment and oral antidiabetic medicines decrease in their hypoglycemic effect is possible

.

should not use Drug along with the medicines oppressing cough as central (codeine, Codterpinum), and the peripheral mechanism of action (eksangit, Prenoxdiazinum).

Neopravdan's

a combination with the medicines causing decrease in bronchial secretion (for example atropine derivatives).

Simultaneous use of ephedrine with theophylline can lead

to strengthening of nausea, nervousness and insomnia. Other medicines or tonics of plant origin (coffee, tea, Coca-Cola) stimulating central nervous system can enhance the stimulating effects of the medicine Bronkholitin on central nervous system at simultaneous application.

by

At patients with AG which receive the accompanying therapy by the ephedrine and adrenergic medicines blocking neurons revealed loss of control of the ABP that can also occur in case of use of other antihypertensive drugs.

by

observes strengthening of vasoconstriction and pressor effects of ergotamine or a metisergid; simultaneous use of ergotamine is not recommended (risk of gangrene).

Effects of ephedrine can be reduced by acidulation and are increased by urine alkalization.

Overdose

At overdose hell, decrease hell, a headache, drowsiness, weakness, fast fatigue, strengthening of manifestations of side reactions, paranoid psychosis, nonsense, hallucinations note nausea, vomiting, fever, loss of appetite, nervous excitement, a tremor of extremities, dizziness, the increased sweating, the complicated urination, increase.

Treatment: gastric lavage, use of activated carbon and symptomatic treatment.

Storage conditions

In original packing at a temperature not above 25 °C. not to freeze! an expiration date after opening of a bottle — 1 month